ABTECT-1 Study on Ulcerative Colitis

A recent study tested ABX464, a new drug for people with moderate to severe ulcerative colitis who have not responded to standard treatments. Participants received either ABX464 or a placebo to determine if the drug can alleviate symptoms and be used safely. If the study is successful, ABX464 could offer a new treatment option for those affected.